Page 1,673«..1020..1,6721,6731,6741,675..1,6801,690..»

Dining and Diabetes classes offered – The Inter-Mountain

Posted: February 15, 2017 at 8:43 am

ELKINS The West Virginia University Extension Service in Barbour and Randolph counties will be offering free Dining with Diabetes classes in Philippi and Elkins.

Elkins classes will be held from 6 to 8 p.m. on March 13, 20, 27 and April 3 at the WVU Randolph County Extension Office. Philippi classes will be held from 10 a.m. to noon on March 14, 21, 28 and April 4 at the Philippi Senior Center.

Dining with Diabetes is a once-a-week class that runs for four weeks with a three-month follow-up class in May. This class is open to those with diabetes and their family members. The classes are free, but space is limited and pre-registration is required by March 8. Participants are encouraged to attend all class sessions.

Those in the class will learn how to prepare meals that are healthy, easy and tasty. Recipes will be demonstrated and participants will have the opportunity to taste each one. Participants will also learn up-to-date information on nutrition, meal planning and exercise as well as how to understand common diabetes-related medical tests. Recipes and handouts will be given to each participant.

Diabetes is a very serious and costly disease, but research has shown that those who learn to manage their blood glucose (sugar) levels, eat healthy and exercise regularly can lower their risk of complications and lead a healthier and more productive life.

The WVU Extension Service cooperates with Davis Medical Center registered dieticians to deliver the program.

For more information or to register for the morning Philippi classes, call the WVU Barbour County Extension office at 304-457-3254 by March 8. For more information or to register for the evening Elkins classes, call the WVU Randolph County Extension office at 304-636-2455 by March 8.

ELKINS Anthony Blackburn, 26, of Elkins, was sentenced to 19 month incarceration for illegally possessing a ...

ELKINS Jason Wayne Russell, 39, of Moorefield, was sentenced to 33 months incarceration for distributing ...

ELKINS Jacob Daniel Anthony, 22, of Weston, was sentenced to five years probation for possession of stolen ...

BUCKHANNON The Office of Admission at West Virginia Wesleyan College will hold the 26th annual Orange & ...

Excerpt from:
Dining and Diabetes classes offered - The Inter-Mountain

Posted in Diabetes | Comments Off on Dining and Diabetes classes offered – The Inter-Mountain

Discover Stem Cells | Eurostemcell

Posted: February 14, 2017 at 10:46 am

An interactive stem cell lesson introducing key concepts in stem cell science to young students. The lesson is intended to be flexible and is made up of a set of short modules, mixing group activities with presentation and facilitator-led discussion.

classroom arranged for group work

2 facilitators: scientists, science communicators or teachers

Assumes students know the body is made up of cells, and that blood contains red and white blood cells.

From my point of view the experience was positive because, in addition to the discussion of the issue relating to stem cells, the aspect of cellular differentiation (a topic that is being discussed in higher classes) was also conveyed and, above all, the construction of this knowledge has come about through a process that makes students active subjects in the process of learning.

Teacher, Italy

Discover stem cells is an easy-to-use lesson packed with games and group activities to engage young students with fundamental ideas in stem cell science. A PowerPoint presentation provides the core structure for the session, but the session is broken up into small modules with regular opportunities for students to explore concepts for themselves. This lesson includes the popular card game, Cell Families.

By the end of the session, students will:

Download the PowerPoint slides and the pdf file called 'Lesson plan and print resources'. You then have everything you need for the lesson and its activites. The lesson plan gives a handy overview of the session and includes a checklist of the materials contained in the pdf that you need to print in advance. For detailed step-by-step guidance on delivering all aspects ofDiscover stem cells, see the facilitators notes in the PowerPoint presentation.

You can now order a print pack of Cell Families cards to use either as part of this lesson or as a stand-alone quick activity. Up to four players compete to collect families of cells, made up of one stem cell and three specialised cells it can produce. A great way to introduce tissue and embyronic stem cells, their roles and properties.

Orderyour pack for just 5 or a class set for 20 on the University of Edinburgh website

Lesson Plan and Print Resources1.88 MB Powerpoint Slides with Facilitator Notes5.82 MB Editable Stem Cells Decision Sheet - Students1.21 MB Editable Takeaway Sheet360.5 KB Stem Cell Family Cards3.9 MB

Acknowledgements

Discover stem cells was created and developed by Ian Chambers and Emma Kemp, MRC Centre for Regenerative Medicine, University of Edinburgh. Important contributions, advice and opportunities to pilot the activities were provided by many colleagues, teachers and students and are detailed within the lesson plan. Particular thanks to Shona Reid of the James Young High School, Livingston, Scotland.Image credits are included within the resources where the images appear.

Permissions:This work is licensed under the Creative Commons Attribution-Share Alike 3.0 Unported License. To view a copy of this license, visithttp://creativecommons.org/licenses/by-sa/3.0/or send a letter to Creative Commons, 171 Second Street, Suite 300, San Francisco, California, 94105, USA

Read more:
Discover Stem Cells | Eurostemcell

Posted in California Stem Cells | Comments Off on Discover Stem Cells | Eurostemcell

Biotechnology: Off To New Highs – Seeking Alpha

Posted: February 14, 2017 at 10:44 am


Seeking Alpha
Biotechnology: Off To New Highs
Seeking Alpha
After an extended period of consolidation, the biotechnology sector appears to be gathering momentum to spike higher and record new 52-week highs. There has been a tangible shift in investor sentiment relating to the regulatory landscape, which has ...

See more here:
Biotechnology: Off To New Highs - Seeking Alpha

Posted in Biotechnology | Comments Off on Biotechnology: Off To New Highs – Seeking Alpha

Why Nigeria Needs To Key Into Biotechnology Global Evolution – Leadership Newspapers

Posted: February 14, 2017 at 10:44 am

A report recently published by the United Nations Food and Agriculture Organisation (FAO) says a total of 8.1 million people are currently facing acute food insecurity in Nigeria.

According to the report, the food crisis, which represents 9 percent of the population, may further deteriorate to 8.7 million in the next lean period of June-August 2017.

It adds that the number of severely food-insecure people may rise to 11 million, as over 2 million people may likely fall into emergency situation, while another 121,000 is prone to famine.

With the current population of over 180 million people, famine, malnutrition and hunger are staring the nation in the face. All these emergency situations are closely linked with the inability to produce enough food to feed the people, which make it obvious that the conventional method of agriculture is not working for us.

Agricultural biotechnology has been suggested as one of the tools that can contribute to solving the food production deficit in the country and has taken concrete steps to entrench biotechnology in agricultural production. This is because Nigeria, like most African countries, may face two daunting challenges in the 21st century: how to feed its growing population and secondly how to adapt to climate change.

Speaking at a one day sensitisation workshop on the appplication of modern biotechnology and biosafety regulation of genetically modified organisms (GMOs) with the theme Agricultural Biotechnology Regulation of Genetically Modified Organisms in Nigeria: Faith Based Perspectives, the director-general of the National Biotechnology Technology Agency (NABDA), Prof. Lucy Ogbadu, stressed that agricultural biotechnology could help Nigeria address the critical issue of food insecurity.

She said the workshop organised by the agency; the National Biosafety Managemt Agency (NBMA); the Open Forum on Agricultural Biotechnology (OFAB) in Africa, Nigeria Chapter, in collaboration with the Catholic Secretariat of Nigeria (CNS) and the Action Family Foundation (AFF) aimed at engaging relevant faith-based and civil society stakeholders on issues of modern biotechnology/biosafety to provide evidence-based advice for policy making.

The NABDA boss, however, noted that the application of modern biotechnology and biosafety regulation of GMOs is one of the most highly debated issues globally, saying Nigeria has not been left out of this debate.

She explained that some stakeholders are still opposed to the establishment in 2015 of the NBMA, an agency saddled with the responsibility to ensure safe and responsible application of this technology for sustainable food production, wealth creation, job creation, poverty alleviation etc. pointing out that the adoption of GMOs by Nigeria is not just a scientific issue, but one with economical, social, and ethical ramifications.

Ogbadu said it became necessary that all groups of stakeholders were carried along at each step of the adoption process, hence, the convening of the workshop with the faith-based organizations.

Giving the workshops objectives, the OFAB Nigeria Chapter coordinator, Dr. Rose Gidado, said it was to raise awareness and sensitise the faith-based groups about issues related to GMOs, their use, and biosafety regulation; address expressed areas of peoples concerns about GMOs; harvest the inputs by participants to guide further refining of the national approaches to the introduction of GMOs; and foster collaboration among stakeholders.

The Bishop of the Catholic Arch Diocese of Abuja, His Eminence, John Cardinal Onaiyekan, said the Catholic Church had nothing against or for the adoption of the controversial GMOs in the country.

The cardinal, represented by his auxiliary, Most. Rev. Anselm Umoren said the Catholic Church did not have anything against GMOs or for it, but believed that biotechnology is about science, which is about many other things that are much more natural than manipulation of genes for certain results.

He said the issue of GMOs would continue to generate tension in the country until all the scientific proofs were substantiated and certified.

Onaiyekan said: The Catholic Church has nothing or against GMO. The issue of GMO will continue to generate tension. I am not sure whether it is not about Catholic Church but it is about humanity in general and it has to do with safety, health and so on.

In his remarks, the director-general of NBMA, Dr Rufus Ebegba, explained that the Federal Government had put adequate measures in place to address concerns that might be raised by any group of people with regard to the safety of biotechnology and GMOs.

The issue of the National Biosafety Management Act is the first measure the federal government has put in place as well as the establishment of the NBMA to ensure that the practice of modern biotechnology is done in compliance with some certain laid down rules and regulations and in that light the agency is well established to see that nothing unsafe as regards to GMOs is allowed into the country.

Nigeria needs not to be bothered as biotechnology is a scientific evolution which is going on globally and Nigeria as a country is adequately prepared for this evolution, he stated.

Speaking to journalists, the vice national president of All Farmers Association of Nigeria, Chief Daniel Okafor, called for more awareness creation on the benefits of biotechnology because Nigerians are still ignornant of the gains of the technology.

He said: We cant do without technology, as a farmer weve been farming for a long time and the yields are not enough. We are talking about increase in yield. We have gone around the world with biotechnology agencies and we noticed that other farmers around the world that have already embraced this technology are doing very well. We need more awareness creation so farmers can also begin to enjoy what their counterparts across the globe are already enjoying.

Visit link:
Why Nigeria Needs To Key Into Biotechnology Global Evolution - Leadership Newspapers

Posted in Biotechnology | Comments Off on Why Nigeria Needs To Key Into Biotechnology Global Evolution – Leadership Newspapers

Biotech’s Next Big Catalyst Could Be Synthetic DNA – ETF Daily News (blog)

Posted: February 14, 2017 at 10:43 am

February 14, 2017 9:21am NASDAQ:IBB

From Jon Markman: It really is a brave new world. Not long ago, a group of prominent scientists announced plans for a project to create synthetic human DNA from scratch.

That seems appropriate for Valentines Day. If you dont like your lover, one day you might just be able to design a new one.

The project will be led by synthetic biologists Jef Boeke, of the Langone Medical Center at New York University, and George Church, of Harvard Medical School. And it will take up where the previous project to read the human genome ended.

In 2003, the Human Genome Project (HGP) was completed. It was supposed to open the door to countless new treatments and cures for illnesses that had plagued humans for centuries. It didnt quite work out that way. It seems understanding the relationship between genes and illness is more complex than scientists originally thought.

The Human Genome Project-write (HGP-write), as the name implies, will attempt to synthetically write human DNA code. The idea is that writing and understanding genetic code made from scratch will help scientists learn more about those complex gene relationships.

And while creating the building blocks for human life in a lab may seem like science fiction, there is some precedent.

In 2010, scientists at the J. Craig Venter Institute created bacteria controlled by a synthetic genome, effectively turning code back into life. HGP-write will be like that experiment, only on a much bigger scale.

Writing DNA is tedious and expensive work. It involves precisely manipulating tiny amounts of chemicals and a DNA molecule.

These chemicals are sugary building blocks designated A, T, C and G and they must be added in the correct amounts and the proper order hundreds of times to change the structure of DNA.

Boeke and Church believe completing HGP-write will shrink development costs for DNA fabrication by a factor of one thousand. If true, that could actually lead to all of the revolutionary treatments promised by the original Human Genome Project. Yet, pesky ethical questions remain.

These are heightened by Churchs own colorful and controversial history. In his 2012 book, Regenesis: How Synthetic Biology Will Reinvent Nature and Ourselves, he wrote about a world where humans with genomes made in the lab become immune to all viruses. According to Church this could be done simply by removing the host material from our genes that viruses need to replicate. And thats just a start. Hes been vocal about his efforts to resurrect the wooly mammoth now that perfectly preserved DNA material from the prehistoric beast has been recovered. Church is also using CRISPR, a gene editing tool he helped develop, to alter pig genes so that their organs can be transplanted into humans. As for humans, hes not shy about his cradle-to-grave outlook.

Hes aggressively in favor of gene editing to avoid potential birth defects and hes working with gene therapies to reverse the aging process. It doesnt help that when hes pressed about ethics, he demurs to comparisons to the industrial revolution. This type of talk often lands scientists in hot water. And Church has been cooked so many times that he should have developed a rubbery exterior by now. Hell need it.

It should take $100 million and ten years to create the human genome from scratch. If the project is successful, scientists say theyll restrict potential use cases to the petri dish to avoid ethical considerations. Thats not exactly Mary Shelleys Frankenstein but it is one giant step closer to Aldous Huxleys Brave New World.

As is often the case in biotech, the most reliable investment for investors in this space will be the proverbial picks and shovels: The makers of lab equipment and disposables, like Becton Dickinson and Co. (BDX), Teleflex Inc. (TFX) and Cantel Medical Corp. (CMD).

Of course, the members of my services Tech Trend Trader receive both more numerous stock recommendations and more detailed analyses of the companies behind them.

The iShares NASDAQ Biotechnology Index ETF (NASDAQ:IBB) rose $0.50 (+0.17%) in premarket trading Tuesday. Year-to-date, IBB has gained 8.07%, versus a 4.10% rise in the benchmark S&P 500 index during the same period.

IBB currently has an ETF Daily News SMART Grade of A (Strong Buy), and is ranked #2 of 36 ETFs in the Health & Biotech ETFs category.

This article is brought to you courtesy of Money And Markets.

Tags: biotech NASDAQ:IBB

Categories: NASDAQ:IBB

Read more here:
Biotech's Next Big Catalyst Could Be Synthetic DNA - ETF Daily News (blog)

Posted in Biotechnology | Comments Off on Biotech’s Next Big Catalyst Could Be Synthetic DNA – ETF Daily News (blog)

Paralyzed Easton Teen Seeking Stem Cell Treatment In Bid To Move Legs Again – Stamford Daily Voice

Posted: February 14, 2017 at 10:43 am

EASTON, Conn. --Hope is a big word in the Standen household in Easton these days.

Through a procedure at the Cell Medicine Institute in Panama, there is a 60 percent to 70 percent chance that Zach Standen a 17-year-old who became paralyzed from the waist down after a car accident last summer may regain some feeling and movement in his legs.

In the procedure, The stem cells are taken from your own bone marrow and human umbilical cords and are re-injected into your body," Zachs mother, Christine Standen, said in a phone interview.

The ultimate goal is for the stem cells from Zach's body to regenerate the nerves and neural connections for him to regain some feeling and function in his legs.

It's extremely important that Zach gets the treatment as soon as possible, his mother said. "He should get the stem cell therapy within a year of the accident since this is when the most healing occurs and before scar tissue is laid down," Christine Standen said. Once this happens, she said, muscle mass is lost and muscles begin to atrophy.

Related story: Easton teen is left paralyzed after car crash.

Zach's family has set up a GoFundMe page to raise the nearly $40,000 needed to pay for the treatment. So far, the page has been shared 687 times. With 313 donations, it has raised $18,194 out of a $100,000 goal.

The family is hoping to raise enough money to get Zach two stem cell treatments, which would greatly increase his chances for recovery.

In addition, a fundraiser has been established to benefit the cause for Zach. Through Feb. 28, a total of 15 percent of the cost of the Arbonne products from this page will be donated to Zach Standens Stem Cell Therapy Fund.

Zach and his mother, as well as Zachs girlfriend, Constance Rude, plan on taking the month-long trip to Panama.

We are hoping that Zach [who attends Joel Barlow High School in Redding] will get his homework assignments ahead of time," she said, adding that he will most likely have to take summer classes or make up some timein the fall.

In a post on Zachs GoFundMe Page, his mother wrote, As of right now, there has been very little progress physically and I can't see him being like this for the rest of his life. No walking, no bowel or bladder control, no sexual function, no feeling. This is no way to live if we can help it, especially for a 17 year old."

She said Zach's spirits are waning. "He is finding it difficult to study and is trying to maintain hope."

Aside from his medical issues, Zach has the life of a typical teenager he goes to school and hangs out with his friends.

Related story: A family seeks support for treatment for paralyzed son.

Zach goes twice a week to physical therapy at Gaylord Hospital in Wallingford. "He is working really hard, every day," said his mother.

Another fundraiser for Zachwill be a concert by the Grayson Hugh & The Moon Hawks & The Bobby Paltauf Band on March 11 at 7 p.m. at the Fairfield Theatre Company. A total of 25 percent of ticket sales will go toward Zach's Stem Cell Therapy Fund.

Christine Standen said she feels extreme gratitude toward for the support the family has received through this tough time. "We are so grateful to the entire community," she said.

For previous Daily Voice articles on Zach Standen, click here and here .

Read more from the original source:
Paralyzed Easton Teen Seeking Stem Cell Treatment In Bid To Move Legs Again - Stamford Daily Voice

Posted in Cell Medicine | Comments Off on Paralyzed Easton Teen Seeking Stem Cell Treatment In Bid To Move Legs Again – Stamford Daily Voice

Dr. Oz takes on those bogus for-profit stem cell clinics–and cuts them to shreds – Chicago Tribune

Posted: February 14, 2017 at 10:43 am

The undercover investigation youre about to see today is going to make you really angry, because were exposing the worst kind of scam one that takes advantage of those most vulnerable, stealing not just their money, but their hope, their dignity.

Thats how Dr. Mehmet Oz introduces a series of segments scheduled to run on his daytime television program Tuesday. His quarry: those for-profit clinics offering supposed stem cell treatments for an implausible host of diseases unproven, unlikelyand very expensive cures.

We reported on this noisome corner of medical pseudo-sciencelast year, outlining theabsence of scientific support for their treatmentand their intensive marketing pitches to hopeful patients. We reported that in a survey of stem cell tourism, stem cell scientist Paul Knoepfler of UC Davis and bioethicist Leigh Turner of the University of Minnesotaidentified 570 clinicsaround the U.S. offering stem cell interventions. Scores were concentrated in such hotspots as Beverly Hills, Phoenixand New York. Many were offering unproven therapies featuring the termstem cell as a marketing veneer.

Dr. Ozs investigation of these clinics is a worthy addition to public awareness. Its must-viewing for patients and families desperate enough to contemplate turning to such clinics for succor, and for state and federal regulators and law enforcement agencies that should be riding herd on thembut have almost universally given them a pass. Oz calls on the Food and Drug Administration and other regulators to step in and stop this now, thats how bad its become.

Weve been critical of Dr. Oz in the past for purveying untested medical nostrums, as have many other critics. But his investigation of the stem cell clinics is a model of public service. He musters his entire arsenal of crowd-pleasing techniques his forceful, impassioneddelivery, his cultivated aura of medical authority, and his credibility with his audience to the best purpose.

The investigation is the product of the shows so-calledmedical unit and its chief of staff, Michael Crupain, a medical doctor and public health specialist who was hired from Consumer Reports about a year and a half ago. At one point during his research for the program Crupain dialed in to a webinar in which prospective patients were recruited by a clinic. It was like watching someone sell a time-share, he told me an observation that made it into the show.

The three segments, which take up about half of Tuesdays scheduled program, include undercover visits to clinics in New York by Elizabeth Leamy, a reporter on the program, along with a former patient. At one point we see a clinic employee claim that hestreated 44 patients for multiple sclerosis, and every single patient had vast improvement. The investigators are pitched $15,000 treatments and encouraged to spread it out on their credit cards. (No insurer will cover these untested and unproven therapies.) One promoter seen on tape acknowledges to the undercover team, We dont know the exact mechanism of everything we do, but counselsthem, We just know that it works, we use it. If it works and its safe [and] its reasonable in cost, you know, why not?

Why not, indeed? Because the targets of these pitches are at the end of their rope, vulnerable to scamsters,and often have to make immense sacrifices to pay the fees. Doctors and others can prey on their vulnerability, Oz observes.

Oz displays a list of the conditions the clinics claim to treat joint pain, autism, Parkinsons, Alzheimers, stroke, emphysema, and blindness, among many others. He explains that its impossible for a one-size-fits-all treatment to cure them all: It defies basic medical know-how, which means they are not telling us the truth. He lucidly describes their supposed technique, which involves extracting stem cells from the patients by liposuction, separating the stem cells by centrifuge and treating them with some sort of enzyme, then reinjecting them in the patients body and waiting for the concoction to do its magic.

He offers a withering assessment of doctors who claim to be engaged in clinical trials of stem cell treatments butask you to give money upfront and mortgage your house and borrow fromyour friends credit cards thats not how medicine should be practiced.

Oz is assisted by talk show host and multiple sclerosis patient Montel Williams and Sally Temple, a stem cell scientistwho is president of theInternational Society for Stem Cell Research. Temple explains that real research into stem cell treatments takes years and aims to develop treatments that can receive FDA approval. She quite properly underscoresthe dangerto legitimate research posed by bogus clinics offering medically dubious treatments.

Theyre saying they can cure a whole host of diseases, and we know they cant, she says. We are really concerned that its going to undermine the genuinely good work thats being done.

Crupain considers the stem cell investigation to be Dr. Oz at his best. Hes right.

Keep up to date with Michael Hiltzik. Follow@hiltzikmon Twitter, see hisFacebook page, or emailmichael.hiltzik@latimes.com.

Return to Michael Hiltzik's blog.

Originally posted here:
Dr. Oz takes on those bogus for-profit stem cell clinics--and cuts them to shreds - Chicago Tribune

Posted in Cell Medicine | Comments Off on Dr. Oz takes on those bogus for-profit stem cell clinics–and cuts them to shreds – Chicago Tribune

Researchers identify cells linked to the development of the heart’s ventricular chambers – Medical Xpress

Posted: February 14, 2017 at 10:43 am

February 14, 2017 The left image is of an embryonic mouse heart, showing the four chambered structure with atria at the top and ventricles at the bottom. The right image is the fluorescent lineage tracing reporter, showing that our newly discovered progenitor cell population contributes specifically to the ventricular chambers of the heart. Credit: Mount Sinai Health System

A population of cells in early development may give rise to the ventricular chambers of the heart, but not the atria, according to a study led by researchers from the Mindich Child Health and Development Institute at the Icahn School of Medicine at Mount Sinai and published today in Nature Communications.

Congenital heart defects are the most common type of birth defect, affecting 35,000 babies in the United States each year, according to the U.S. Department of Health and Human Services. Many of these defects originate as the heart chambers are forming. While much is known about the development of the heart, the formation of the four distinct chambers of the heart has lacked thorough understanding.

Using a model that traces cell lineage in mice, investigators studied the protein-coding gene Foxa2, primarily associated with endoderm and ectoderm development during embryogenesis. They discovered a population of progenitor cells expressing Foxa2 during early development that gave rise to cardiovascular cells of both the left and right ventricular chambers, but not the atria. Their research showed that atrial-ventricular segregation may occur long before the morphological establishment of differentiated cardiac structures.

"An in-depth understanding of the formation of the heart chambers will enable us to better comprehend the biology behind detrimental heart defects and how best to address them," said lead investigator Nicole Dubois, PhD, Assistant Professor in the Department of Cell, Developmental and Regenerative Biology at the Icahn School of Medicine at Mount Sinai. "In addition to informing our understanding of early heart development, we hope that these findings will also lead to new protocols for the generation of ventricular cardiomyocytes in cell culture that could potentially be used in therapeutic settings."

"There is a lot we still don't understand about this population, or the function of Foxa2 during the formation of the heart, but we think these findings provide a powerful new system to answer some of the most relevant open questions about how early heart development occurs," said Evan Bardot, PhD student and first author of the Nature Communications study.

Explore further: New mouse model helps explain gene discovery in congenital heart disease

More information: Nature Communications, DOI: 10.1038/NCOMMS14428

Scientists now have clues to how a gene mutation discovered in families affected with congenital heart disease leads to underdevelopment of the walls that separate the heart into four chambers. A Nationwide Children's Hospital ...

Congenital heart defects (CHDs) are a leading cause of birth defect-related deaths. Understanding how genetic alterations cause such defects is complicated by the fact that many of the critical genes are unknown, and those ...

Using cardiac imaging during heart surgery can detect serious residual holes in the heart that may occur when surgeons repair a child's heart defect, and offers surgeons the opportunity to close those holes during the same ...

Loyola Medicine is the only center in the Midwest enrolling patients in a landmark clinical trial of a new procedure to treat a life-threatening heart rhythm disorder called ventricular tachycardia.

Scientists at the Gladstone Institutes linked a single gene mutation to two types of heart disease: one causes a hole in the heart of infants, and the other causes heart failure. Using cells donated by a family with the mutation, ...

Food fortified with folic acid, a B vitamin required in human diets for numerous biological functions, was associated with reduced rates of congenital heart defects, according to new research in the American Heart Association's ...

A population of cells in early development may give rise to the ventricular chambers of the heart, but not the atria, according to a study led by researchers from the Mindich Child Health and Development Institute at the ...

Researchers have projected that aggressively lowering blood pressure could help prevent more than 100,000 deaths in the U.S. each year.

Obesity and a diet high in fat could lead to a harmful activation of the immune system, increasing a person's risk of heart disease, according to a study led by Queen Mary University of London (QMUL).

While boxes of decadent chocolate treats, celebratory champagne and romantic, high-calorie dinners may dance in your mind as a way to celebrate Valentine's Day, your heart may be pining for something else. With Valentine's ...

Strokes and heart attacks often strike without warning. But, a unique application of a medical camera could one day help physicians know who is at risk for a cardiovascular event by providing a better view of potential problem ...

Matters of the heart can be complicated, but York University scientists have found a way to create 3D heart tissue that beats in synchronized harmony, like a heart in love, that will lead to better understanding of cardiac ...

Adjust slider to filter visible comments by rank

Display comments: newest first

Interesting that in the development from fertilized egg to fully grown human being we witness true evolution - changes from a single ancestor cell into an extreme highly complex life form. Right before our eyes, in our lifetime. Fully observed, repeatable and verifiable. No need to invent non-existing missing links since it's all there - right in front of us. Everywhere. True, full blooded, indisputable evolution - one kind into another into another into another into another.............all programmed to the last tee by a superlatively ingenious super intelligent being otherwise known as the Creator. Strange then that highly educated scientists do not want to see or acknowledge the evidence for the existence of said Creator.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Read more here:
Researchers identify cells linked to the development of the heart's ventricular chambers - Medical Xpress

Posted in Cell Medicine | Comments Off on Researchers identify cells linked to the development of the heart’s ventricular chambers – Medical Xpress

Annual Summit on Cell Therapy and Molecular Medicine …

Posted: February 14, 2017 at 10:42 am

Sessions/Tracks

Track 1: Cell Therapy

Cell therapy or cytotherapy is the transfer of cells into a patient with a goal of improving the disease. From beginning blood transfusions were considered to be the first type of cell therapy to be practised as routine. Later, Bone marrow transplantation has also become a well established concept which involves treatment of many kind of blood disorders including anemia, leukemia, lymphyoma and rare immunodeficiency diseases. Alternative medical practitioners perform cell therapy in the form of several different names including xenotransplant therapy, glandular therapy, and fresh cell therapy. It has been claimed by the proponents of cell therapy that it has been used successfully to repair spinal cord injuries, strengthen weaken immune system, treats autoimmune diseases like AIDS, help patients with neurological disorders like Alzheimers disease, parkinsons disease and epilepsy.

Related Conferences

3rd International Conference & Exhibition on Tissue Preservation and Biobanking, Aug 23-24 2017, San Francisco, USA; Annual Summit onCell Signalingand Cancer Therapy, Sep 27-28, 2017, Chicago, USA; 8th World Congress and Expo on Cell & Stem Cell Research, March 20-22, 2017 in Orlando, Florida, USA; Annual Summit on Cell Therapyand Molecular Medicine, Sep 27-28, 2017, Chicago, USA; 2nd World Biotechnology Congress, Dec 4-5 2017, Sao Paulo, Brazil; Spring Symposium of the Netherlands Society of Gene & Cell therapy (NVGCT), 17 March 2017, Lunteren, The Netherlands; British Society for Gene and Cell Therapy (BSGCT) Public Engagement 2017, March 27-28, 2017 Oxford, UK; 19th International Conference on Cell and Gene Therapy ICCGT 2017, April 19-21, 2017, Singapore; International Society for BioProcess Technology 7th Spring Meeting Viral vectors and vaccines, March 16-17, 2017, Washington, DC and 2nd Annual Genome Editing & Engineering Conference, Feb 6-7 2017, San Diego, CA.

Track 2: Gene Therapy

Gene therapy basically involves the introduction or alteration of genetic material within a cell or organism with an intention of curing the disease. Both cell therapy and gene therapy are overlapping fields of biomedical research with the goals of repairing the direct cause of genetic diseases in DNA or cellular population respectively. The discovery of recombinant DNA technology in the 1970s provided tools to efficiently develop gene therapy. Scientists use these techniques to readily manipulate viral genomes, isolate genes and identify mutations involved in human disease, characterize and regulate gene expressions, and engineer various viral and non viral vectors. Various long term treatments for anemia, haemophilia, cystic fibrosis, muscular dystrophy, Gauschers disease, lysosomal storage diseases, cardiovascular diseases, diabetes and diseases of bones and joints are resolved through successful gene therapy and are elusive today.

Related Conferences

Annual Summit onCell Signaling and Cancer Therapy, Sep 27-28, 2017, Chicago, USA; AnnualSummit on Cell Therapyand Molecular Medicine, Sep 27-28, 2017, Chicago, USA;2nd World Biotechnology Congress, Dec 4-5 2017, Sao Paulo, Brazil; 3rd International Conference & Exhibition on Tissue Preservation and Biobanking, Aug 23-24 2017, San Francisco, USA; 8thWorld Congress and Expo on Cell & Stem Cell Research, March 20-22, 2017, Orlando, Florida, USA; 10th Australasian Gene Therapy Society Meeting (AGCTS), October 17-20, 2017, Sydney, Australia; XXV Congress of the European Society of Gene and Cell Therapy (ESGCT), Berlin, Germany.

Track 3:Molecular Medicine

Molecular Medicineis a branch of medicine that develops ways to diagnose and treat diseases by understanding the ways genes, proteins and other cellular molecules work. It is a broad field where physical, chemical, biological,bioinformatics, and medical techniques are used to describe molecular structures and mechanisms, identify fundamental molecular and genetic errors of the disease, and to develop molecular interventions to correct them. Molecular Medicine has now a days proved to be an exciting field of research as some of the recent advancements has led to improved clinical benefits for human health. These are LPS- induced inflammatory response is suppressed by Wnt inhibitors, Dickkopf-1 and LGK974, Selective inhibition ofEbolaentry with selective estrogen receptor modulators by disrupting the endolysosomal calcium, ApoA-IV improves insulin sensitivity and glucose uptake in mouse adipocytes via PI3K-Akt Signalling and many more.

Related Conferences

AnnualSummit onCell TherapyandMolecular Medicine, Sep 27-28, 2017, Chicago, USA; 2nd WorldBiotechnologyCongress, Dec 4-5 2017, Sao Paulo, Brazil;3rd International Conference & Exhibition onTissue PreservationandBiobanking, Aug 23-24 2017, San Francisco, USA; Annual Summit onCell Signalingand Cancer Therapy, Sep 27-28, 2017, Chicago , USA;8thWorld Congress and Expo onCell&Stem CellResearch, March 20-22, 2017, Orlando, Florida, USA;Annual conference of British Society forGeneandCell Therapy(BSGCT), May 3-6, 2017, Cardiff, Wales, UK; International Society forCellular Therapy(ISCT) 23rdAnnual Meeting, May 10-13, 2017, London, UK; American Society ofGeneandCell Therapy(ASGCT) 20thAnnual Meeting , May 14-19, 2017, Washington, DC; Gordon Research Conference:Viruses&Cells, May 17-19, 2017, Lucca, Italy and WorldAdvanced TherapiesandRegenerative MedicineCongress 2017, May 24-26, 2017, London, UK.

Track 4:Immunotherapy

Due to rapidly advancing field of cancer immunology in past few years, there has been production of several new methods of treating cancer called Immunotherapies. Immunotherapy is a type of treatment that increases the strength of immune response against tumors either by stimulating the activities of specific components of immune system or by counteracting signals produced by cancer cells that suppress immune responses. Some types of immunotherapy are also called as biologic therapy or biotherapy. Recent advancements in cancer immunotherapies have provided new therapeutic approaches. These include tumor-associated macrophages as treatment targets in oncology, in-situ activation of platelets with checkpoint inhibitors for post-surgical cancer immunotherapy, immune checkpoint blockade and associated endocrinopathies and many more.

Related Conferences

3rd International Conference & Exhibition onTissue PreservationandBiobanking, Aug 23-24 2017, San Francisco, USA; Annual Summit onCell Signalingand Cancer Therapy, Sep 27-28, 2017, Chicago, USA; 8thWorld Congress and Expo onCell&Stem CellResearch, March 20-22, 2017 in Orlando, Florida, USA; Annual Summit onCell TherapyandMolecular Medicine, Sep 27-28, 2017, Chicago, USA; 2nd WorldBiotechnologyCongress, Dec 4-5 2017, Sao Paulo, Brazil; Spring Symposium of the Netherlands Society ofGene&Cell therapy(NVGCT), 17 March 2017, Lunteren, The Netherlands; British Society forGeneandCell Therapy(BSGCT) Public Engagement 2017, March 27-28, 2017 Oxford, UK; 19thInternational Conference onCellandGene Therapy ICCGT 2017, April 19-21, 2017, Singapore; International Society for BioProcess Technology 7thSpring Meeting Viral vectorsandvaccines, March 16-17, 2017, Washington, DC and 2ndAnnualGenome Editing&EngineeringConference, Feb 6-7 2017, San Diego, CA.

Genetic Medicine orMedical Geneticsis the branch of medicine that differs from human genetics, and involves the diagnosis and management of hereditary disorders. Human genetics may or may not apply to medicine, but medical genetics refers to the application of genetics to medical care. Genetic Medicine basically involves different areas such asgene therapy, personalized medicine, predictive medicine and the rapidly emerging new medical specialty. Now a days, medical genetics has wide range of scopes in many conditions involving birth defects and dysmorphology,autism, mental retardation, skeletal dysplasia, mitochondrial disorders, cancer genetics, connective tissue disorders and some more.

Related Conferences

Annual Summit onCell Signalingand Cancer Therapy, Sep 27-28, 2017, Chicago, USA; AnnualSummit onCell TherapyandMolecular Medicine, Sep 27-28, 2017, Chicago, USA;2nd WorldBiotechnologyCongress, Dec 4-5 2017, Sao Paulo, Brazil; 3rd International Conference & Exhibition onTissue PreservationandBiobanking, Aug 23-24 2017, San Francisco, USA; 8thWorld Congress and Expo onCell&Stem CellResearch, March 20-22, 2017, Orlando, Florida, USA; 10thAustralasianGene TherapySociety Meeting (AGCTS), October 17-20, 2017, Sydney, Australia; XXV Congress of the European Society ofGeneandCell Therapy(ESGCT), Berlin, Germany.

Track 6: Clinical Trials in Cell and Gene Therapy

A clinical trial is a research study that tests how well new medical approaches work on people and determines if a treatment is safe and effective. The new cell and gene therapies (CGTs) that are advancing from the laboratory into early phase clinical trials has proven to be a complex task even for experienced investigators . As a result of wide variety of CGT products and their potential applications, a case by case assessment is warranted for the design of each clinical trial. Some of the latest and advanced clinical trials include safety and efficacy trial of AAV gene therapy in patients with CNGA3 Achromatopsia, A clinical trial for treatment of Aromatic L- Amino acid Decarboxylase (AADC) deficiency using AAV2-hAADC- An expansion and Glypican 3-specific Chimeric antigenic receptor expressed in T cells for patients with pediatric solid tumors.

Related Conferences

AnnualSummit onCell TherapyandMolecular Medicine, Sep 27-28, 2017, Chicago, USA; 2nd WorldBiotechnologyCongress, Dec 4-5 2017, Sao Paulo, Brazil;3rd International Conference & Exhibition onTissue PreservationandBiobanking, Aug 23-24 2017, San Francisco, USA; Annual Summit onCell Signalingand Cancer Therapy, Sep 27-28, 2017, Chicago , USA;8thWorld Congress and Expo onCell&Stem CellResearch, March 20-22, 2017, Orlando, Florida, USA;Annual conference of British Society forGeneandCell Therapy(BSGCT), May 3-6, 2017, Cardiff, Wales, UK; International Society forCellular Therapy(ISCT) 23rdAnnual Meeting, May 10-13, 2017, London, UK; American Society ofGeneandCell Therapy(ASGCT) 20thAnnual Meeting , May 14-19, 2017, Washington, DC; Gordon Research Conference:Viruses&Cells, May 17-19, 2017, Lucca, Italy and WorldAdvanced TherapiesandRegenerative MedicineCongress 2017, May 24-26, 2017, London, UK.

Track 7: Cell Therapy Bioprocessing

Cell Therapy Bioprocessing activity mainly focuses to accelerate the safe, cost- effective translations and clinical efficacious of cell therapies into commercial products. This activity covers the entire range of cell therapy activities as well as tissue engineering. In order to succeed, commercial success of at least a few late-stage products are required to develop which will be funded to develop next generation tools and technologies for this field. Recent achievements include, preclinical filing for Phase 1 clinical trials for cell therapy in acute spinal cord injury, clinical proof of concept studies in tissue- engineered trachea, clinical trials for tissue-engineered larynx and routine clinical practice in the regeneration of corneas. The future research priorities will focus on novel cell and bioprocess engineering techniques in order to improve the manufacturing efficacy and methods for health technology assessment to support rapid clinical adoption of new cell therapies.

Related Conferences

3rd International Conference & Exhibition onTissue PreservationandBiobanking, Aug 23-24 2017, San Francisco, USA; Annual Summit onCell Signalingand Cancer Therapy, Sep 27-28, 2017, Chicago, USA; 8thWorld Congress and Expo onCell&Stem CellResearch, March 20-22, 2017 in Orlando, Florida, USA; Annual Summit onCell Therapyand Molecular Medicine, Sep 27-28, 2017, Chicago, USA; 2nd WorldBiotechnologyCongress, Dec 4-5 2017, Sao Paulo, Brazil; Spring Symposium of the Netherlands Society ofGene&Cell therapy(NVGCT), 17 March 2017, Lunteren, The Netherlands; British Society forGeneandCell Therapy(BSGCT) Public Engagement 2017, March 27-28, 2017 Oxford, UK; 19thInternational Conference onCellandGene Therapy ICCGT 2017, April 19-21, 2017, Singapore; International Society for BioProcess Technology 7thSpring Meeting Viral vectorsandvaccines, March 16-17, 2017, Washington, DC and 2ndAnnualGenome Editing&EngineeringConference, Feb 6-7 2017, San Diego, CA.

Cell and Gene Therapy products manufacturing focuses on various strategies like the manufacturing process must protect the product, patient, should focus on product characterization, process control, high throughput and parallel processing to achieve scale. The process/analytical development throughout clinical trials involve ongoing, iterative development of manufacturing process and characterization of profile and FDA expecting increasing control and characterization as clinical development progresses. Steps involved in individualized manufacturing and running in parallel for high throughput involves cell selection, expansion, activation, centrifugation and cryopreservation.

Related Conferences

Annual Summit onCell Signalingand Cancer Therapy, Sep 27-28, 2017, Chicago, USA; AnnualSummit onCell Therapyand Molecular Medicine, Sep 27-28, 2017, Chicago, USA;2nd WorldBiotechnologyCongress, Dec 4-5 2017, Sao Paulo, Brazil; 3rd International Conference & Exhibition onTissue PreservationandBiobanking, Aug 23-24 2017, San Francisco, USA; 8thWorld Congress and Expo onCell&Stem CellResearch, March 20-22, 2017, Orlando, Florida, USA; 10thAustralasianGene TherapySociety Meeting (AGCTS), October 17-20, 2017, Sydney, Australia; XXV Congress of the European Society ofGeneandCell Therapy(ESGCT), Berlin, Germany.

Track 9: Rare Diseases & Orphan drugs

Rare diseases are life-threatening or chronically debilitating conditions, affecting no more than 5 in 10,000 persons in the European Community according to the Regulation (EC) N. 141/2000 of the European Parliament and of the Council. It is estimated that between 6000 to 8000 distinct rare diseases affect up to 6% of the total EU population. Therefore, these conditions can be considered rare if taken individually but they affect a significant proportion of the European population when considered as a single group. Several initiatives have been taken at international, European and national level to tackle public health as well as research issues related to diagnosis, prevention, treatment and surveillance of these diseases. An Orphan drug can be defined as the one that is used to treat an orphan disease. An orphan disease in USA is defined as the one that affects fewer than 200000 individuals, but in Japan the number is 50,000 and in Australia is 2000. In past 20 years efforts have been made to encourage companies to develop orphan drugs. The Orphan Drug Act in the USA (1983) was succeeded by similar legislation in Japan (1985), Australia (1997), and the European Community (2000). The encouragement takes three forms: tax credits and research aids, simplification of marketing authorization procedures, and extended market exclusively.

Related Conferences

Annual Summit onCell Therapyand Molecular Medicine, Sep 27-28, 2017, Chicago, USA; 2nd WorldBiotechnologyCongress, Dec 4-5 2017, Sao Paulo, Brazil;3rd International Conference & Exhibition onTissue PreservationandBiobanking, Aug 23-24 2017, San Francisco, USA; Annual Summit onCell Signalingand Cancer Therapy, Sep 27-28, 2017, Chicago, USA;8thWorld Congress and Expo onCell&Stem CellResearch, March 20-22, 2017, Orlando, Florida, USA;Annual conference of British Society forGeneandCell Therapy(BSGCT), May 3-6, 2017, Cardiff, Wales, UK; International Society forCellular Therapy(ISCT) 23rdAnnual Meeting, May 10-13, 2017, London, UK; American Society ofGeneandCell Therapy(ASGCT) 20thAnnual Meeting , May 14-19, 2017, Washington, DC; Gordon Research Conference:Viruses&Cells, May 17-19, 2017, Lucca, Italy and WorldAdvanced TherapiesandRegenerative MedicineCongress 2017, May 24-26, 2017, London, UK.

Stem cells can self renew themselves and differentiate or develop into more specialised cells. They are the foundation for every organ and tissue in our body. Due to this ability of the stem cells, they have tremendous promise to help us understand and treat a wide range of diseases, injuries and other health related problems. Bone marrow transplantation is the most widely used stem cell therapy , but some of the therapies are derived from umbilical cord blood are also in use today. Likewise, blood stem cells are used to treat diseases of blood, a therapy that has saved thousands of lives of children with leukemia. Some bone, skin and corneal (eye) injuries and diseases can be treated by grafting or implanting tissues and the healing process relies on stem cells with implanted tissue.Regenerative medicines aims to replace tissues or organs that have been damaged by disease, trauma, or congenital issues which is in contrast to the current clinical strategy that focuses primarily on treating the symptoms. These regenerative medicines have wide appropriateness in treating degenerative scatters including dermatology, cardio vascular, and neuro degenerative diseases. Cell treatment is the quickest developing fragment of regenerative drug and this undeveloped cell treatment is making up the biggest part of this business sector.

Related Conferences

3rd International Conference & Exhibition onTissue PreservationandBiobanking, Aug 23-24 2017, San Francisco, USA; Annual Summit onCell Signalingand Cancer Therapy, Sep 27-28, 2017, Chicago, USA; 8thWorld Congress and Expo onCell&Stem CellResearch, March 20-22, 2017 in Orlando, Florida, USA; Annual Summit onCell Therapyand Molecular Medicine, Sep 27-28, 2017, Chicago, USA; 2nd WorldBiotechnologyCongress, Dec 4-5 2017, Sao Paulo, Brazil; Spring Symposium of the Netherlands Society ofGene&Cell therapy(NVGCT), 17 March 2017, Lunteren, The Netherlands; British Society forGeneandCell Therapy(BSGCT) Public Engagement 2017, March 27-28, 2017 Oxford, UK; 19thInternational Conference onCellandGene Therapy ICCGT 2017, April 19-21, 2017, Singapore; International Society for BioProcess Technology 7thSpring Meeting Viral vectorsandvaccines, March 16-17, 2017, Washington, DC and 2ndAnnualGenome Editing&EngineeringConference, Feb 6-7 2017, San Diego, CA.

Cancer is a process where the cells grow aberrantly and this growth of cancer cells results in damage of normal tissues, causing loss of function and often pain. The cancer therapeutic drugs are those drugs that block the growth and spread of cancer by interfering with specific molecules (molecular targets) that are involved in the growth, progression and spread of cancer. Moreover, gene therapy approaches may be designed to directly kill tumor cells using tumor killing viruses, or through the introduction of genes termed as suicide genes into the tumor cells. The Food and Drug Administration (FDA) has approved many cancer therapies in order to treat specific types of cancers. To develop targeted therapies it requires the identification of good targets that is, those targets that play a key role in cancer cell growth and survival. One way to identify potential targets is to compare the amounts of individual proteins in cancer cells with those present in normal cells. Gene silencing has also been designed to inhibit the expression of specific genes which are activated or over expressed in cancer cells and can drive tumor growth, blood vessel formation and allow resistance for chemotherapy.

Related Conferences

Annual Summit onCell Signalingand Cancer Therapy, Sep 27-28, 2017, Chicago, USA; Annual SummitSummit onCell Therapyand Molecular Medicine, Sep 27-28, 2017, Chicago, USA;2nd WorldBiotechnologyCongress, Dec 4-5 2017, Sao Paulo, Brazil; 3rd International Conference & Exhibition onTissue PreservationandBiobanking, Aug 23-24 2017, San Francisco, USA; 8thWorld Congress and Expo onCell&Stem CellResearch, March 20-22, 2017, Orlando, Florida, USA; 10thAustralasianGene TherapySociety Meeting (AGCTS), October 17-20, 2017, Sydney, Australia; XXV Congress of the European Society ofGeneandCell Therapy(ESGCT), Berlin, Germany.

Track 12:Nuclear Medicine

Nuclear medicineis a branch of medical imaging that involves the application of radioactive substances called radiotracers that are generally injected into the bloodstream, inhaled or swallowed. Theradiotracerthen travels through the area being examined and gives off energy in the form of gamma rays, which are detected by a special camera and a computer to create images of inside the body. It is used to diagnose or determine the severity of or treat different types of diseases like many types of cancers, heart disease, neurological disease, gastrointestinal disease, and other abnormalities inside the body. As nuclear medicine techniques are able to identify molecular activity within the body, they offer the capability to detect diseases in its very early stages as well as a patients immediate response to therapeutic interventions. There are two most common imaging methods in nuclear medicine, one isSingle Photon Emission Computed Tomographyor SPECT and the other is Positron Emission Tomography or PET scans.

Related Conferences

AnnualSummit onCell TherapyandMolecular Medicine, Sep 27-28, 2017, Chicago, USA; 2nd WorldBiotechnologyCongress, Dec 4-5 2017, Sao Paulo, Brazil;3rd International Conference & Exhibition onTissue PreservationandBiobanking, Aug 23-24 2017, San Francisco, USA; Annual Summit onCell Signalingand Cancer Therapy, Sep 27-28, 2017, Chicago , USA;8thWorld Congress and Expo onCell&Stem CellResearch, March 20-22, 2017, Orlando, Florida, USA;Annual conference of British Society forGeneandCell Therapy(BSGCT), May 3-6, 2017, Cardiff, Wales, UK; International Society forCellular Therapy(ISCT) 23rdAnnual Meeting, May 10-13, 2017, London, UK; American Society ofGeneandCell Therapy(ASGCT) 20thAnnual Meeting , May 14-19, 2017, Washington, DC; Gordon Research Conference:Viruses&Cells, May 17-19, 2017, Lucca, Italy and WorldAdvanced TherapiesandRegenerative MedicineCongress 2017, May 24-26, 2017, London, UK.

Track 13: Advances in Cell Engineering, Imaging and Screening

In recent times, advancements in cell engineering, imaging and screening has reached a great height in the field of science & technology and also in the business world. It has attracted many scientists from academia and also established or emerging companies in the field to present their latest scientific achievements and exciting technological solutions through presentations in several sessions. This has helped in improving the scientific knowledge among the people, scientists, researchers and exhibitors from all over the world thus enhancing their scientific curiosity and providing robust solutions against technological issues.

Related Conferences

3rd International Conference & Exhibition onTissue PreservationandBiobanking, Aug 23-24 2017, San Francisco, USA; Annual Summit onCell Signalingand Cancer Therapy, Sep 27-28, 2017, Chicago, USA; 8thWorld Congress and Expo onCell&Stem CellResearch, March 20-22, 2017 in Orlando, Florida, USA; Annual Summit onCell TherapyandMolecular Medicine, Sep 27-28, 2017, Chicago, USA; 2nd WorldBiotechnologyCongress, Dec 4-5 2017, Sao Paulo, Brazil; Spring Symposium of the Netherlands Society ofGene&Cell therapy(NVGCT), 17 March 2017, Lunteren, The Netherlands; British Society forGeneandCell Therapy(BSGCT) Public Engagement 2017, March 27-28, 2017 Oxford, UK; 19thInternational Conference onCellandGene Therapy ICCGT 2017, April 19-21, 2017, Singapore; International Society for BioProcess Technology 7thSpring Meeting Viral vectorsandvaccines, March 16-17, 2017, Washington, DC and 2ndAnnualGenome Editing&EngineeringConference, Feb 6-7 2017, San Diego, CA.

Track 14: Synthetic Biology and Genetic modifications of cells

Synthetic Biology is one of the emerging field of research that can be broadly described as the design and construction of novel artificial biological pathways, organisms or devices or the redesigning of existing natural biological systems. Genome editing with engineered nucleases is a type of genetic engineering in which DNA is either inserted, replaced or deleted in the genome of an organism using engineered nucleases or molecular scissors. These nucleases hence create site specific double stranded breaks (DSBs) at desired locations in the genome. The induced double stranded breaks are repaired through non homologous end- joining (NHEJ) or homologous recombination (HR), thus resulting in targeted mutations (edits). Scientists now a days use various engineered nucleases in order to bring desired changes in the human genome.

Related Conferences

Annual Summit onCell Signalingand Cancer Therapy, Sep 27-28, 2017, Chicago, USA; Annual SummitSummit onCell TherapyandMolecular Medicine, Sep 27-28, 2017, Chicago, USA;2nd WorldBiotechnologyCongress, Dec 4-5 2017, Sao Paulo, Brazil; 3rd International Conference & Exhibition onTissue PreservationandBiobanking, Aug 23-24 2017, San Francisco, USA; 8thWorld Congress and Expo onCell&Stem CellResearch, March 20-22, 2017, Orlando, Florida, USA; 10thAustralasianGene TherapySociety Meeting (AGCTS), October 17-20, 2017, Sydney, Australia; XXV Congress of the European Society ofGeneandCell Therapy(ESGCT), Berlin, Germany.

Biobanking 2016

Sensing the raising importance of Biobanks,Conference LLChosted the 2nd International Conference & Exhibition on Tissue Preservation and Biobanking(Biobanking-2016), duringSeptember 12-13, 2016inPhiladelphia, USAwith a theme Global Innovations in Tissue preservation and Biobanking Technologies. Benevolent response and active participations were received from the Editorial Board Members of Conference LLC Journals as well as from the Biobank project managers, Embryologists, Hematologists, Stem Cell researchers, Scientists, Doctors, Students and Leaders from the fields of Cell and Stem Cell Research, who made this event inspiringly successful.

TheBiobanking-2016 Conferencewas carried out through various sessions with discussions on the following thought provoking and cerebrating scientific tracks:

Human cancer biobank

Biorepository & Biospecimen

Disease based biobank

Cryopreservation Methods

Vitrification

Brain Banking

Biobank Ethics

Biobank in Microbiology

Next Generation Biobanking

Biobank in Genomics

Fertility biobanks

Germplasm Bank

Immune banking

Biobank Applications

Biobanking Informatics

Market Analysis in Biobanking

Tissue engineering

. Stem cell Biobanking

The Organizing Committee would like to thank the moderatorDr.Mary A Hall,UT health sciences, USAandDr. Elena Salvaterra,Air liquide Sanit Service, Italyfor their contribution which resulted in smooth functioning of the conference.

The conference was initiated and embarked with an opening ceremony followed by Keynote presentations, workshop and a series of lectures delivered by both Honorable Guests and members of the Keynote forum. The peerless people who promulgated the theme with their Keynote presentations were;

Kelvin GM Brockbank-Ice-free banking by vitrification of tissues(Tissue Testing Technologies LLC, USA)

Simone Chevalier- The Quebec procure prostate cancer biobank: A unique resource for comprehensive studies of the disease(McGill Urology Director of Research, Canada)

Stephen C Peiper-Biospecimen repository genomic annotations in the precision medicine era(Thomas Jefferson University, USA)

Fiorella Guadagni-Biobanks as a pivotal research infrastructure in precision medicine (San Raffaele Rome University, Italy)

Yoed Rabin-Mechanical stress and structural integrity in vitrification(Carnegie Mellon University, USA)

Mitchel C. Schiewe-Applying the KISS principle with vitrification: Safety and quality control concerns in assisted reproductive technologies(Ovagen Fertility, USA)

Various sessions were chaired and co-chaired by: Kelvin GM Brockbank (Tissue Testing Technologies LLC, USA);Simone Chevalier (McGill Urology Director of Research, Canada), USA; Charles W Wang, (Shanghai Jiao Tong University, China);Yaffa Rubinstein (National Institute of Health, USA).

Conference Series LLC has taken the privilege of felicitating Biobanking-2016 Organizing Committee, Editorial Board Members and Keynote Speakers who supported for the success of this conference.

The esteemed guests, keynote speakers and researchers shared their innovative research and vast experience through their informative presentations at the podium ofBiobanking-2016.We are glad to inform that all accepted abstracts for the conference have been published inJournal of Tissue Science & Engineering: Open Accessas a special issue.

We are also obliged to various experts, company representatives and other eminent scientists who supported the conference by facilitating the discussion forums. We sincerely thank the Organizing Committee Members for their gracious presence, support, and assistance. With the unique feedback from the conference,Conference Series LLC would like to proudly announce the commencement of the 3rd International Conference & Exhibition on Tissue Preservation and Biobanking" to be organized duringAugust 23-24, 2017atSan Francisco, USA.

Mark your calendars for the upcoming Conference; we are hoping to see you soon!

For more details:http://biobanking.conferenceseries.com/

See more here:
Annual Summit on Cell Therapy and Molecular Medicine ...

Posted in Cell Therapy | Comments Off on Annual Summit on Cell Therapy and Molecular Medicine …

INDYCAR legend Foyt plans to have stem cell therapy – INDYCAR

Posted: February 14, 2017 at 10:42 am

(This story originally appeared as exclusive content on the Verizon INDYCAR Mobile app. To download the app for smartphones, click here.)

AVONDALE, Ariz. At 82, A.J. Foyt's body has literally been beaten beyond his years.

The first four-time winner of the Indianapolis 500 has experienced everything from a broken back at a 1964 NASCAR race in Riverside, California, to two badly broken feet and legs in a horrible crash at Road America in a 1991 Indy car race.

Foyt retired from racing on pole qualifying day at the 1993 Indianapolis 500, but retirement hasn't been much easier. He was stung more than 200 times from an attack of killer bees in 2005, trapped under an overturned bulldozer on his Texas ranch in 2007 and had knee replacements and a hip replacement. In November 2014, Foyt underwent triple-bypass heart surgery and remained in the hospital for weeks afterward because of complications.

Foyt has survived it all but not without a struggle. He now is looking for a fountain of youth and told the Verizon INDYCAR Mobile App that he will undergo stem cell therapy in Cancun, Mexico.

They have to cut away some of the tissue from my stomach and it takes 8-10 weeks for it to grow back to produce the stem cells, Foyt said in an exclusive interview. I'll probably have it done soon so that we can begin the treatment within the next two to three months.

Adult stem cells are able to grow and become a cell for a specific tissue or organ, according to the National Institutes of Health. They are different from embryonic stem cells, which come from fertilized eggs or aborted fetuses. Embryonic stem cells can turn into cells for nearly any tissue in the body.

The procedure is not performed in the United States, so Foyt has found a medical facility in Mexico that can do the treatment that regenerates newer and younger cells. He said he will have stem cells injected into each ankle and shoulder, as well as into his blood.

It used to be you would have to go to Germany to get this procedure, but now it's available in Cancun and that is probably where I'll have it done, Foyt said Saturday during the Verizon IndyCar Series open test at Phoenix Raceway. I'm not in good health like I used to be and, if my son Larry hadn't taken over (running) the team four years ago, I would have had to shut it down. It's something he likes to do and I'm backing him 100 percent.

Foyt said he feels good to be his age after all the crap that I've been through.

I feel better this year than I did last year, Foyt continued. If I get to feeling bad, I probably won't show up at the race. But I'm going to do that stem cell deal. My wife, Lucy, has been pretty sick lately. Dan Pastorini (the former NFL quarterback) did it and it helped him. Peyton Manning (the former Indianapolis Colts and Denver Broncos quarterback) did it for his neck and it really helped him. Tony Dorsett (the former Dallas Cowboys running back) did it, so I think we should try it.

Go here to read the rest:
INDYCAR legend Foyt plans to have stem cell therapy - INDYCAR

Posted in Cell Therapy | Comments Off on INDYCAR legend Foyt plans to have stem cell therapy – INDYCAR

Page 1,673«..1020..1,6721,6731,6741,675..1,6801,690..»